Accueil   Diary - News   All news Biom’Up announces the success of its IPO, raising close to €38.1 million on Euronext Paris

Biom’Up announces the success of its IPO, raising close to €38.1 million on Euronext Paris

 

First initial public offering in the healthcare sector on the Euronext regulated market in Paris in the last 6 months

 

Saint-Priest, France, October 11, 2017 – Biom’Up, specialist of surgical hemostasis, today announces the success of its IPO on compartment C of the Euronext regulated market in Paris (“Euronext Paris”).


“I am very pleased to announce today the success of our IPO on the regulated market of Euronext in Paris. I welcome the new French, European and American shareholders, and thank them for their trust. This operation was made possible by the empowerment and the financial investment of the management team (Bill Spotnitz, João-Paulo Alves and Jan Ohrstrom), as well as the support of the historical shareholders. We are now in the best conditions to deploy our range of hemostatic products - especially HEMOBLAST™ Bellows - in Europe and North America. We will maintain our R&D investments and conduct new clinical studies to gain access to new surgical indications for the benefit of patients and clinicians.” says Etienne Binant, Chief Executive Officer of Biom’Up.

 

 

Read the press release